Effects of anti-estrogens on cell invasion and survival in pituitary adenoma cells: A systematic study

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• Estrogen plays a significant role in pituitary adenoma development.
• The precise molecular mechanisms of pituitary adenoma formation remain largely unknown.
• Limited research exists on the impact of selective estrogen receptor modulators (SERMs) on pituitary adenoma cell behavior.

Purpose of the Study:

• To investigate the effects of fulvestrant and three SERMs (bazedoxifene, clomifene, raloxifene) on pituitary adenoma cell lines.
• To assess the modulation of cell migration, invasion, and survival by SERMs.
• To explore the underlying molecular mechanisms of SERM action in pituitary adenomas.

Main Methods:

• Treatment of pituitary adenoma cell lines (AtT20, TtT/GF, GH3) with fulvestrant and SERMs.
• Cell survival assays to determine IC50 values.
• Analysis of cell migration and invasion.
• Measurement of Caspase 3/7 activity.
• Western blot analysis for p53 and ERK1/2 activation.

Main Results:

• Clomifene was the most potent SERM, inhibiting cell survival across all tested cell lines.
• Raloxifene and bazedoxifene also demonstrated effectiveness in reducing cell survival.
• All tested SERMs impacted the migratory and invasive properties of pituitary adenoma cells.
• SERM treatment induced apoptosis, evidenced by increased Caspase 3/7 activity.
• Specific molecular changes observed include p53 activation in TtT/GF cells and ERK1/2 deactivation in AtT20 cells.
• Fulvestrant showed efficacy only in the GH3 cell line.

Conclusions:

• SERMs, particularly clomifene, exhibit significant potential in inhibiting pituitary adenoma cell proliferation, migration, and invasion.
• The observed induction of apoptosis and modulation of key signaling pathways suggest a promising therapeutic avenue.
• SERMs may offer a broadly applicable clinical strategy for managing pituitary adenomas.